Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 23 Apr 2023
Despite Improvement Efforts, the "State of the Air" Report Highlights Issues.
Read Full NewsA 36-year-old woman with a 2-year history of hairline recession and eyebrow thinning shows marked regrowth after early multimodal therapy with dutasteride, tofacitinib, and intralesional steroids.
With a mental health care provider shortage and many patients’ seeking mental health support, primary care doctors have stepped up to the front lines.
While tuberculosis spread is not significant nationally, lack of awareness of the latent form of the condition raises legitimate concerns for potential future infections.
The U.S. and the Global Fund to Fight AIDS, Tuberculosis and Malaria are stepping up efforts to broaden access to Gilead's HIV prevention drug, with a goal of reaching 3...
Fewer resources through Gavi, the Vaccine Alliance, may limit vaccine administration at the local level.
Monthly injectable HIV therapy shows lower treatment failure than oral regimens in individuals with adherence challenges.
A subgroup analysis hints that chemotherapy may be skipped after complete resection, but the finding needs further study.
1.
Sarah Ferguson was identified as having malignant melanoma. These are the most recent therapies.
2.
Top FDA Official Exits; SCOTUS Takes Up Obamacare Case; Texas Doc Suspended
3.
Does pollution cause cancer?
4.
The need for more Latinx participants in Alzheimer's trials is urgent.
5.
Adjuvant therapy for hepatocellular carcinoma after curative treatment: Several unanswered questions
1.
Unlocking the Key to Treating Lymphoma: New Innovations in Cancer Research
2.
Unlocking Immunity: TILs, Immunotherapy Biomarkers, and Toxicity Management in Oncology
3.
Skin-Sparing Mastectomy: Balancing Cancer Control with Cosmetic Results
4.
Immunotherapy Breakthroughs: Transforming Cancer Care Across All Oncology Fields
5.
Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
2.
Thromboprophylaxis In Medical Settings
3.
Navigating the Complexities of Ph Negative ALL - Part X
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
5.
From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge